These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 26940484)

  • 1. Current practice in treatment approach for bullous pemphigoid: comparison between national surveys from the Netherlands and the UK.
    Meijer JM; Jonkman MF; Wojnarowska F; Wiliams HC; Kirtschig G
    Clin Exp Dermatol; 2016 Jul; 41(5):506-9. PubMed ID: 26940484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The approach of dermatologists in the UK to the treatment of bullous pemphigoid: results of a national survey.
    Taghipour K; Mohd Mustapa MF; Highet AS; Venning VA; Kirtschig G
    Clin Exp Dermatol; 2013 Apr; 38(3):311-3. PubMed ID: 23517364
    [No Abstract]   [Full Text] [Related]  

  • 3. British Association of Dermatologists' guidelines for the management of bullous pemphigoid 2012.
    Venning VA; Taghipour K; Mohd Mustapa MF; Highet AS; Kirtschig G
    Br J Dermatol; 2012 Dec; 167(6):1200-14. PubMed ID: 23121204
    [No Abstract]   [Full Text] [Related]  

  • 4. Management of vitiligo. Results of a questionnaire among dermatologists in The Netherlands.
    Njoo MD; Bossuyt PM; Westerhof W
    Int J Dermatol; 1999 Nov; 38(11):866-72. PubMed ID: 10583624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence-based management of bullous pemphigoid.
    Daniel BS; Borradori L; Hall RP; Murrell DF
    Dermatol Clin; 2011 Oct; 29(4):613-20. PubMed ID: 21925006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of bullous pemphigoid: recommendations for immunomodulatory treatments.
    Kirtschig G; Khumalo NP
    Am J Clin Dermatol; 2004; 5(5):319-26. PubMed ID: 15554733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dermatologists and allergists have far more experience and use more complex treatment regimens in the treatment of atopic dermatitis than other physicians.
    Henderson RL; Fleischer AB; Feldman SR
    J Cutan Med Surg; 2001; 5(3):211-6. PubMed ID: 11685667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Azathioprine in dermatology: a survey of current practice in the U.K.
    Tan BB; Lear JT; Gawkrodger DJ; English JS
    Br J Dermatol; 1997 Mar; 136(3):351-5. PubMed ID: 9115914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant therapy of bullous pemphigoid with mycophenolate mofetil: old drug, new use.
    Ratnam KV
    Singapore Med J; 2001 Oct; 42(10):482-4. PubMed ID: 11874153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survey of bullous pemphigoid in an Italian university hospital: clinical-epidemiological characteristics and follow-up.
    Balestri R; Odorici G; Patrizi A; Infusino SD; Magnano M; Bardazzi F
    G Ital Dermatol Venereol; 2018 Oct; 153(5):613-618. PubMed ID: 28079339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey.
    van de Kerkhof PC; Reich K; Kavanaugh A; Bachelez H; Barker J; Girolomoni G; Langley RG; Paul CF; Puig L; Lebwohl MG
    J Eur Acad Dermatol Venereol; 2015 Oct; 29(10):2002-10. PubMed ID: 25885420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pattern of topical corticosteroid prescribing in the United States, 1989-1991.
    Stern RS
    J Am Acad Dermatol; 1996 Aug; 35(2 Pt 1):183-6. PubMed ID: 8708016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of bullous pemphigoid: the European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology.
    Feliciani C; Joly P; Jonkman MF; Zambruno G; Zillikens D; Ioannides D; Kowalewski C; Jedlickova H; Kárpáti S; Marinovic B; Mimouni D; Uzun S; Yayli S; Hertl M; Borradori L
    Br J Dermatol; 2015 Apr; 172(4):867-77. PubMed ID: 25827742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Interpretation of 2021 French Guidelines for the Therapeutic Management of Bullous Pemphigoid].
    Wang SH; Zuo YG
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2022 Oct; 44(5):828-836. PubMed ID: 36325781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Profile of bullous pemphigoid. A report of 47 cases].
    Triki Ben Ammar S; Mokhtar I; Fazaa B; Kharfi M; Kamoun MR
    Tunis Med; 2000 Oct; 78(10):584-8. PubMed ID: 11190743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Whole body application of a potent topical corticosteroid for bullous pemphigoid.
    Terra JB; Potze WJ; Jonkman MF
    J Eur Acad Dermatol Venereol; 2014 Jun; 28(6):712-8. PubMed ID: 23551654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sulfamethoxypyridazine-responsive pemphigoid nodularis: a report of two cases.
    Gach JE; Wilson NJ; Wojnarowska F; Ilchyshyn A
    J Am Acad Dermatol; 2005 Aug; 53(2 Suppl 1):S101-4. PubMed ID: 16021154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Bullous pemphigoid--a cause of itching of the skin with increasing incidence].
    Huilaja L; Försti AK; Tasanen K
    Duodecim; 2015; 131(16):1443-50. PubMed ID: 26485937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clarithromycin as a steroid sparing agent for the management of infantile bullous pemphigoid.
    Tso S; Petrof G; Unter S; Humphreys F
    BMJ Case Rep; 2018 Jan; 2018():. PubMed ID: 29374651
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical manifestations in 100 Japanese bullous pemphigoid cases in relation to autoantigen profiles.
    Tanaka M; Hashimoto T; Dykes PJ; Nishikawa T
    Clin Exp Dermatol; 1996 Jan; 21(1):23-7. PubMed ID: 8689764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.